Cargando…

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy

Immune checkpoint inhibitors (ICI) based on anti-CTLA-4 (αCTLA-4) and anti-PD1 (αPD1) are being tested in combination with different therapeutic approaches including other immunotherapies such as neoantigen cancer vaccines (NCV). Here we explored, in two cancer murine models, different therapeutic c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvatori, Erika, Lione, Lucia, Compagnone, Mirco, Pinto, Eleonora, Conforti, Antonella, Ciliberto, Gennaro, Aurisicchio, Luigi, Palombo, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810847/ https://www.ncbi.nlm.nih.gov/pubmed/35110563 http://dx.doi.org/10.1038/s41541-022-00433-9

Ejemplares similares

Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition
por: Lione, Lucia, et al.
Publicado: (2021)

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
por: Aurisicchio, Luigi, et al.
Publicado: (2019)

Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
por: D’Alessio, Federico, et al.
Publicado: (2023)

Linear DNA amplicons as a novel cancer vaccine strategy
por: Conforti, Antonella, et al.
Publicado: (2022)

The perfect personalized cancer therapy: cancer vaccines against neoantigens
por: Aurisicchio, Luigi, et al.
Publicado: (2018)

DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
por: Compagnone, Mirco, et al.
Publicado: (2022)

A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
por: Conforti, Antonella, et al.
Publicado: (2023)

Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells
por: Manco, Roberta, et al.
Publicado: (2023)

Are Genetic Vaccines the Right Weapon against COVID-19?
por: Conforti, Antonella, et al.
Publicado: (2020)

A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets
por: Martins, Mathias, et al.
Publicado: (2023)

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
por: Aurisicchio, Luigi, et al.
Publicado: (2023)

Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants
por: Massacci, Alice, et al.
Publicado: (2020)

Emerging Cancer Vaccines: The Promise of Genetic Vectors
por: Aurisicchio, Luigi, et al.
Publicado: (2011)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
por: Conforti, Antonella, et al.
Publicado: (2022)

Mitochondrial Proteins as Source of Cancer Neoantigens
por: Prota, Gennaro, et al.
Publicado: (2022)

A novel minigene scaffold for therapeutic cancer vaccines
por: Aurisicchio, Luigi, et al.
Publicado: (2014)

Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study
por: Aurisicchio, Luigi, et al.
Publicado: (2020)

Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
por: Witt, Kristina, et al.
Publicado: (2021)

Regulated and prolonged expression of mIFNα in immunocompetent mice mediated by a helper-dependent adenovirus vector
por: Aurisicchio, L, et al.
Publicado: (2002)

Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients
por: Roscilli, Giuseppe, et al.
Publicado: (2014)

Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma
por: Impellizeri, Joseph A., et al.
Publicado: (2018)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Safety and efficacy of a genetic vaccine targeting Telomerase plus chemotherapy for the therapy of canine B-cell lymphoma
por: Gavazza, Alessandra, et al.
Publicado: (2013)

Comparative expression pathway analysis of human and canine mammary tumors
por: Uva, Paolo, et al.
Publicado: (2009)

NeoFox: annotating neoantigen candidates with neoantigen features
por: Lang, Franziska, et al.
Publicado: (2021)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Lymphoma neoantigens
por: Elias, Joshua E.
Publicado: (2018)

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
por: Nguyen, Kim Bich, et al.
Publicado: (2023)

Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model
por: Yoshimoto, Yuya, et al.
Publicado: (2014)

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
por: Noto, Alessia, et al.
Publicado: (2013)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform
por: Fridman, Arthur, et al.
Publicado: (2012)

Determinants for Neoantigen Identification
por: Garcia-Garijo, Andrea, et al.
Publicado: (2019)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines
por: Peruzzi, Daniela, et al.
Publicado: (2009)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Neoantigens as potential vaccines in hepatocellular carcinoma
por: Repáraz, David, et al.
Publicado: (2022)

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
por: Petrizzo, Annacarmen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9qrq0chletp9kl4e4pqe0qqpk1